Daewon Pharmaceutical Co., Ltd. (003220.KS)
KRW 14020.0
(-1.2%)
KRW 14020.0
(-1.2%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 1139.91 KRW | -24.5% |
| 2022 | 1509.75 KRW | 358.39% |
| 2021 | 329.36 KRW | -60.14% |
| 2020 | 826.31 KRW | -34.68% |
| 2019 | 1265.08 KRW | 14.94% |
| 2018 | 1100.64 KRW | 132.22% |
| 2017 | 473.96 KRW | -47.72% |
| 2016 | 906.62 KRW | 14.73% |
| 2015 | 790.24 KRW | 14.77% |
| 2014 | 688.52 KRW | 27.66% |
| 2013 | 539.35 KRW | 34.19% |
| 2012 | 401.93 KRW | -16.04% |
| 2011 | 478.70 KRW | -18.95% |
| 2010 | 590.61 KRW | 12.39% |
| 2009 | 525.51 KRW | 30.23% |
| 2008 | 403.52 KRW | 1.03% |
| 2007 | 399.41 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | 436.34 KRW | 1133.99% |
| 2024 Q2 | -36.11 KRW | -108.28% |
| 2023 Q3 | 260.15 KRW | -32.48% |
| 2023 Q2 | 385.30 KRW | -16.11% |
| 2023 Q1 | 459.31 KRW | 224.83% |
| 2023 FY | - KRW | -24.5% |
| 2023 Q4 | 35.36 KRW | -86.41% |
| 2022 Q1 | 495.10 KRW | 92.25% |
| 2022 FY | - KRW | 358.39% |
| 2022 Q2 | 349.00 KRW | -29.51% |
| 2022 Q3 | 522.00 KRW | 49.57% |
| 2022 Q4 | 141.40 KRW | -72.91% |
| 2021 FY | - KRW | -60.14% |
| 2021 Q1 | -380.78 KRW | -464.0% |
| 2021 Q2 | 139.81 KRW | 136.72% |
| 2021 Q4 | 257.53 KRW | -12.75% |
| 2021 Q3 | 295.15 KRW | 111.11% |
| 2020 Q1 | 344.89 KRW | -16.24% |
| 2020 Q4 | 104.61 KRW | -33.05% |
| 2020 Q3 | 156.26 KRW | -21.76% |
| 2020 FY | - KRW | -34.68% |
| 2020 Q2 | 199.72 KRW | -42.09% |
| 2019 Q3 | 290.86 KRW | 1.25% |
| 2019 FY | - KRW | 14.94% |
| 2019 Q2 | 287.27 KRW | 9.59% |
| 2019 Q4 | 411.74 KRW | 41.56% |
| 2019 Q1 | 262.13 KRW | -14.47% |
| 2018 Q3 | 231.84 KRW | -4.66% |
| 2018 FY | - KRW | 132.22% |
| 2018 Q1 | 305.05 KRW | 635.24% |
| 2018 Q4 | 306.47 KRW | 32.19% |
| 2018 Q2 | 243.17 KRW | -20.29% |
| 2017 Q1 | 146.09 KRW | -35.97% |
| 2017 Q4 | 41.49 KRW | -89.25% |
| 2017 FY | - KRW | -47.72% |
| 2017 Q3 | 385.98 KRW | 494.06% |
| 2017 Q2 | -97.95 KRW | -167.05% |
| 2016 FY | - KRW | 14.73% |
| 2016 Q2 | 199.86 KRW | 16.98% |
| 2016 Q1 | 170.85 KRW | -32.37% |
| 2016 Q3 | 315.91 KRW | 58.07% |
| 2016 Q4 | 228.15 KRW | -27.78% |
| 2015 FY | - KRW | 14.77% |
| 2015 Q1 | 169.78 KRW | -29.6% |
| 2015 Q4 | 252.64 KRW | 85.57% |
| 2015 Q3 | 136.14 KRW | -43.14% |
| 2015 Q2 | 239.42 KRW | 41.02% |
| 2014 Q2 | 133.38 KRW | 34.58% |
| 2014 Q1 | 99.11 KRW | -40.33% |
| 2014 FY | - KRW | 27.66% |
| 2014 Q4 | 241.17 KRW | 4.4% |
| 2014 Q3 | 231.00 KRW | 73.19% |
| 2013 Q2 | 169.61 KRW | 88.18% |
| 2013 Q3 | 134.13 KRW | -20.92% |
| 2013 Q4 | 166.10 KRW | 23.84% |
| 2013 FY | - KRW | 34.19% |
| 2013 Q1 | 90.13 KRW | -38.28% |
| 2012 Q3 | 92.90 KRW | -6.49% |
| 2012 Q4 | 146.04 KRW | 57.2% |
| 2012 FY | - KRW | -16.04% |
| 2012 Q1 | 74.84 KRW | -37.8% |
| 2012 Q2 | 99.35 KRW | 32.75% |
| 2011 Q1 | 154.25 KRW | 462.09% |
| 2011 Q2 | 142.52 KRW | -7.6% |
| 2011 Q3 | 96.19 KRW | -32.51% |
| 2011 Q4 | 120.33 KRW | 25.1% |
| 2011 FY | - KRW | -18.95% |
| 2010 Q2 | 189.44 KRW | -24.0% |
| 2010 Q1 | 249.26 KRW | 84.19% |
| 2010 FY | - KRW | 12.39% |
| 2010 Q3 | 212.90 KRW | 12.38% |
| 2010 Q4 | -42.60 KRW | -120.01% |
| 2009 Q4 | 135.33 KRW | -0.54% |
| 2009 FY | - KRW | 30.23% |
| 2009 Q3 | 136.07 KRW | -4.92% |
| 2009 Q2 | 143.11 KRW | 23.86% |
| 2009 Q1 | 115.54 KRW | 1.63% |
| 2008 Q3 | 63.34 KRW | -47.32% |
| 2008 Q2 | 120.23 KRW | 11.41% |
| 2008 Q1 | 107.92 KRW | 19.65% |
| 2008 FY | - KRW | 1.03% |
| 2008 Q4 | 113.69 KRW | 79.49% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q4 | 90.20 KRW | -18.42% |
| 2007 Q3 | 110.57 KRW | 13.23% |
| 2007 Q2 | 97.65 KRW | -5.55% |
| 2007 Q1 | 103.39 KRW | 0.0% |